

# New Pathways & New Sources of Evidence, What do we need?


## EUnetHTA

European network for  
Health Technology Assessment

Better science, Better health, London, October 21, 2014


*Finn Børlum Kristensen  
Adjunct professor, University of Southern Denmark  
Executive Committee Chairman, Director, EUnetHTA Secretariat  
Danish Health and Medicines Authority (EUnetHTA Coordinator),  
Copenhagen, Denmark*

# HTA informs




Based on Kristensen FB et al. Seminars in Colon and Rectal Surgery, 2002; 13: 96 – 103

# Health Technology Life-cycle



# The Domains of the HTA Core Model<sup>®</sup>

## - assessing dimensions of value



# Some Reflections from the HTA perspective

In order to better capture value

- how “far” could IMI extend it’s remit in terms of involving academic environments beyond the fields of science applied in “pre-clinical, clinical, (pharmaco-)epidemiological, regulatory, economics”?
- HTA would have a lot of MAPPs related research needs *in the fields listed above and in the fields of e.g. organisation of healthcare, and patient and societal aspects* to be transferred into IMI and Horizon 2020 consortia questions.

# HTA 2.0 Europe

**EUnetHTA Conference,  
Rome, October 30 – 31 2014**

**Teaming up for Value**